Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Carbohydrate Metabolism

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Physician Training on Diagnosis and Counseling of Overweight and Obese Asian Patients.

Journal of racial and ethnic health disparities·2016

Same author

An ulcerating foot lesion.

American family physician·2005

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.

Grant C Fowler¹, Deepa A Vasudevan

¹Department of Family and Community Medicine, University of Texas Medical School at Houston, 6431 Fannin JJL #324, Houston, TX 77030, USA.

Southern Medical Journal

|August 7, 2010

Summary

Achieving comprehensive glycemic control in type 2 diabetes mellitus requires managing glycated hemoglobin A1c (HbA1c), postprandial glucose (PPG), and fasting plasma glucose (FPG) levels. Combination therapies offer effective management with minimal risk of hypoglycemia and weight gain.

Related Experiment Videos

Last Updated: Jun 10, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Area of Science:

Endocrinology
Metabolic Diseases
Pharmacology

Background:

Comprehensive glycemic control is crucial for managing type 2 diabetes mellitus (T2DM).
Minimizing blood glucose fluctuations is essential to prevent microvascular and macrovascular complications.
HbA1c alone may not reflect daily glucose variability.

Purpose of the Study:

To emphasize the importance of reducing HbA1c, PPG, and FPG for effective glycemic control.
To highlight patient safety, particularly minimizing hypoglycemia.
To discuss the role of combination therapies in T2DM management.

Main Methods:

Review of current understanding of glycemic control targets in T2DM.
Analysis of the limitations of HbA1c as a sole indicator of glucose control.
Evaluation of combination pharmacotherapies for T2DM.

Main Results:

Glycemic control necessitates targeting HbA1c, PPG, and FPG.
Hypoglycemia poses significant risks, including cognitive impairment.
Combination regimens can achieve glycemic targets with reduced hypoglycemia and weight gain.

Conclusions:

Effective T2DM management requires a multi-faceted approach to glycemic control.
Combination therapies offer a viable strategy for achieving optimal glycemic targets while prioritizing patient safety.
Minimizing hypoglycemia and weight gain are key considerations in treatment selection.